Altimmune, Inc: Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Altimmune (Nasdaq: ALT) reported Q2 2026 results and a business update. The company initiated the global PERFORMA Phase 3 MASH trial, reported positive topline RECLAIM Phase 2 AUD data, and completed enrollment in the RESTORE Phase 2 ALD trial. Cash, cash equivalents and investments were $519 million as of June 30, 2026. R&D was $18.7 million and net loss $22.8 million.
How this was made
The 30-second read
Why it matters
The release combines (1) new clinical execution milestones across all three indications, (2) registrational-endpoint framing for AUD, and (3) a cash runway snapshot, which together can shift probability-weighted valuation and near-term sentiment.
Market read
Traders may reprice Altimmune’s near-to-medium term catalyst path as PERFORMA Phase 3 starts and AUD topline results are framed around FDA registrational endpoints, supported by a $519M cash balance.
What to watch
The ALD endpoint hierarchy change and the 2027 topline timing push key value inflection further out, so near-term trading may hinge more on MASH and AUD than ALD.
Background
Altimmune is a late clinical-stage biopharmaceutical developing pemvidutide for MASH, AUD, and ALD, with FDA designations including Breakthrough Therapy for MASH and Fast Track for AUD.
Ticker impact
Altimmune reported Q2 2026 cash of $519M and disclosed new clinical milestones, including starting the global PERFORMA Phase 3 MASH trial and positive RECLAIM Phase 2 AUD topline data.
Likely positive bias into the webcast, with follow-through dependent on investor focus on PERFORMA Phase 3 readiness and AUD registrational-endpoint details.
The article contains multiple primary, time-sensitive disclosures: initiation of a Phase 3 trial, positive Phase 2 topline with FDA-recognized registrational endpoints, and completion of ALD enrollment, alongside a sizable cash balance.
Market effects
Adds incremental validation for late-stage GLP-1/glucagon dual-agonist liver and AUD pipelines, potentially supporting sentiment toward similar metabolic/liver franchises.
Limited direct regional spillover; primarily US biotech sentiment.
Global Phase 3 design and European regulatory engagement plans may modestly influence broader international liver-disease trial expectations.
Counterpoint
Positive Phase 2 toplines do not guarantee Phase 3 success; investors may discount the PERFORMA Phase 3 initiation until protocol details, event rates, and interim risk controls are clearer.
Key entities
- companyAltimmune, Inc.
Nasdaq-listed late clinical-stage biopharmaceutical developing pemvidutide for liver diseases and AUD.
- drug_programPemvidutide
Investigational 1:1 glucagon/GLP-1 dual receptor agonist in Phase 3 MASH and Phase 2 AUD/ALD programs.
- clinical_trialPERFORMA
Global Phase 3, randomized, double-blind, placebo-controlled study in MASH with 52-week data readout anticipated in 2029.
- clinical_trialRECLAIM
Phase 2 trial in AUD reporting positive topline results, including FDA-recognized registrational endpoints.
- clinical_trialRESTORE
Phase 2 trial in ALD with completed enrollment and amended protocol assessing liver benefits at Week 48 then Week 24.
